Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia

American Journal of Hematology

Volumn 82, Issue 4, 2007, Pages 276-282

  Mousa, Shaker A ^a   Ahmad, Sarfraz ^b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c FLORIDA HOSPITAL   (United States)

Author keywords

GPIIb IIIa receptor inhibitors; Heparin induced thrombocytopenia; Heparin platelet factor 4 antibodies; Patient management; Platelet activation aggregation; Thrombosis

Indexed keywords

3 [[[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETYL]AMINO] N (BUTOXYCARBONYL)ALANINE; ADRENALIN; ANTIBODY; ARACHIDONIC ACID; COLLAGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; IODINE 125; ROXIFIBAN; SEROTONIN; THROMBIN; THROMBOCYTE FACTOR 4;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ISOTOPE LABELING; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AMINO ACIDS; CELLS, CULTURED; HEPARIN; HUMANS; ISOXAZOLES; KRUPPEL-LIKE TRANSCRIPTION FACTORS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REPRESSOR PROTEINS; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA;

EID: 34147164522     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20801     Document Type: Article

References (40)

1. Spinler SA, Dager W. Overview of heparin-induced thrombocytopenia. Am J Health-Syst Pharm 2003;60 (Suppl 5):S5-S11.
2. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005;127 (Suppl 2):35S-45S.
3. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch Intern Med 2004;164:361-369.
4. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 2003;101:31-37.
5. Fabris F, Ahmad S, Cella G, et al. Pathophysiology of heparin-induced thrombocytopenia: Clinical and diagnostic implications-A review. Arch Pathol Lab Med 2000;124:1657-1666.
6. Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332: 1330-1335.
7. Ahmad S, Untch B, Haas S, et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: Implications in the HIT pathogenesis. Mol Cell Biochem 2004;258:163-170.
8. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced Thrombocytopenia, 3rd ed. New York: Marcel Dekker: 2004. pp 107-148.
9. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95, 96.
10. Hughes M, Hayward CPM, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000;96:188-194.
11. Warkentin TE. Clinical picture of HIT. In: Warkentin TE, Greinacher A, editors. Heparin-induced Thrombocytopenia, 3rd ed. New York: Marcel Dekker; 2004. pp 53-106.
12. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;343:1286-1292.
13. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210-215.
14. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (Suppl 3):311S-337S.
15. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-350.
16. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
17. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005;146:341-346.
18. Mousa SA, Bozarth JM, Forsythe MS, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/ IIIa receptor antagonist. Circulation 1994;89:3-12.
19. Mousa SA, Bozarth JM, Seiffert D, et al. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/ IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Blood Coagul Fibrinolysis 2005;16:165-171.
20. Murphy J, Wright RS, Gussak I, et al. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs 2003;3:101-112.
21. Serebruany VL, Malinin AI, O'Connor CM, et al. Roxifiban oral compound kinetics evaluation trial-1 platelet substudy. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J 2003;146:91-98.
22. Fossler MJ, Ebling WF, Ma S, et al. Integrated pharmacokinetic/ pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers. J Clin Pharmacol 2002;42:1326-1334.
23. Ahmad S, Walenga JM, Jeske WP, et al. Functional heterogeneity of anti-heparin-platelet factor 4 antibodies: Implications in the pathogenesis of HIT syndrome. Clin Appl Thromb Hemost 1999;5 (Suppl 1):S32-S37.
24. Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype, and functionality of anti-heparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia: The pathogenic role of IgG. Thromb Res 2002;105:117-123.
25. Pouplard C, Lochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97:3300-3302.
26. Weyrich AS, Lindermann S, Zimmermann GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003;1:1897-1905.
27. Fareed J, Walenga JM, Hoppensteadt DA, et al. Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 1999;25 (Suppl 1):37-42.
28. Kannan M, Ahmad S, Ahmad F, et al. Functional characterization of antibodies against heparin-platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: Relevance to inflammatory markers. Blood Coagul Fibrinolysis 2005;16:487-490.
29. Mousa SA, Bozarth JM, Lorelli W, et al. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: Comparative platelet binding profiles with c7E3. J Pharmacol Exp Ther 1998;286:1277-1284.
30. Pedicord DL, Thomas BE, Mousa SA, et al. Glycoprotein IIb/ IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998;90:247-258.
31. Keulartz IM, Beguin S, de Zwaan C, et al. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet-rich plasma from patients. Thromb Haemost 1998;80:370-371.
32. Herault JP, Peyrou V, Savi P, et al. Effect of SR121566A, a potent GPIIb/IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998;79:383-388.
33. Mak KH, Kottke-Marchant K, Brooks LM, et al. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Thromb Haemost 1998;80:989-993.
34. 2 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 1997;89:137-146.
35. Polgar J, Eichler P, Greinacher A, et al. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998;91:549-554.
36. Walenga JM, Jeske WP, Wallis DE, et al. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999;25 (Suppl 1):77-81.
37. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thrombelastography: Differentiation among glycoprotein IIb/ IIIa antagonists. Arterioscler Thromb Vasc Biol 2000;20:1162-1167.
38. Mousa SA, Bozarth JM, Naik UP, et al. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: Distinct binding profile for roxifiban. Br J Pharmacol 2001;133:331-336.
39. Mousa SA, Forsythe MS. Comparison of the effect of different platelet GPIIb/IIIa antagonists on the dynamics of platelet/ fibrin-mediated clot strength induced using thrombelastography. Thromb Res 2001;104:49-56.
40. Pieniaszek HJ Jr, Sy SKB, Ebling W, et al. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. J Clin Pharmacol 2002;42:738-753.